# name
Comparison of the Analytical and Clinical Performance of Five
                Tests for the Detection of Human Papillomavirus Genital
                Infection

# metadata.dc.description.abstract[].value
HPV-based screening provides greater protection against cervical
                cancer (CC) than cytology-based strategies. Currently, several
                molecular diagnostic assays for the detection of human
                papillomavirus (HPV) are available. In this study, we analyzed 5
                different HPV testing and genotyping techniques (Hybrid Capture
                2 [HC2; Qiagen, Hilden, Germany], AnyplexTMII HPV28 [Anyplex;
                Seegene, Seoul, Korea], Linear Array [Roche, Branchburg, NJ,
                USA], GP5+/6+ PCR-EIA-RH [Labo Bio-medical Products, Rijswijk,
                The Netherlands] and CLART2 [Genomica, Madrid, Spain]) in 295
                women referred to the hospital Colposcopy Clinic from 2007 to
                2008 due to positive HPV test results or an abnormal Pap test.
                DNA extraction for HPV genotyping was performed in cervical
                sample specimens after Pap test and HPV detection by HC2. The
                inclusion criteria were: (1) adequate cervical sampling with
                sufficient material for the Pap test and HPV detection and
                genotyping, and (2) colposcopically-directed biopsy and/or
                endocervical curettage. HC2 showed the highest sensitivity for
                high-grade squamous intraepithelial lesion and CC (HSIL+)
                detection (96.1%), but all the HPV genotyping tests showed a
                higher specificity. (Anyplex 86.8%; Linear Array 86.0%; GP5+/6+
                78.8%; CLART2 76.5%). The agreement between HC2 results and the
                other techniques was similar: 82.4%, kappa=0.650 for Anyplex;
                83.4%, kappa=0.670 for Linear Array, 79.93%, kappa=0.609 for
                GP5+/6+ and 82.4%, kappa=0.654 for CLART2. HPV 16 and/or 18
                infection was a risk factor for underlying HSIL+ in the
                univariate analysis. Anyplex showed the highest risk of
                underlying HSIL+ after positive HPV 16 and/or 18 tests (OR 31.1;
                95% IC 12.1-80.0).

# metadata.dc.relation.isformatof[].value
Versió postprint del document publicat a:
                http://dx.doi.org/10.1016/j.jviromet.2017.07.009

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Comparison of the Analytical and Clinical Performance of Five
                Tests for the Detection of Human Papillomavirus Genital
                Infection